Reduced medication reimbursement doesn't always mean less value. The High Authority for Health evaluates medical interest separately from cost considerations.
Medication reimbursement and medical interest
A medication with reduced reimbursement is not necessarily useless. Its medical interest is evaluated by the High Authority for Health, while the price and budget considerations are addressed afterward.Government aims for drug cost savings
The government has set a goal of achieving 3 billion euros in savings on drug expenses by 2027, as part of the Social Security budget. The bill for the 2027 Social Security funding was rejected in first reading by deputies on October 23 but will continue to be debated in the Senate.Decree on reimbursement changes remains in effect
This budget debate should not be confused with a decree from August 21, 2026, which was already published to prepare certain reductions in reimbursement. The rejection of the budget does not automatically cancel this decree.Savings may not directly impact all patients
These savings do not necessarily affect patients directly. The 3 billion euros mentioned include other measures beyond reduced reimbursements, such as price reductions or contributions requested from pharmaceutical companies.Patient impact varies by medication and coverage
For a patient, the actual impact can vary depending on the medication, its reimbursement rate, the final decision applied, and the coverage provided by a health insurance supplement. Two practical questions arise: what portion of the cost will be covered by the Health Insurance?
